Cocrystal Pharma
COCP
21 hedge funds and large institutions have $2.08M invested in Cocrystal Pharma in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 15 increasing their positions, 3 reducing their positions, and 8 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 3
11.94% more ownership
Funds ownership: 1.16% → 13.1% (+12%)
22% less funds holding
Funds holding: 27 → 21 (-6)
47% less capital invested
Capital invested by funds: $3.95M → $2.08M (-$1.87M)
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$11.7K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.44K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.34K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$643 |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$482 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$50.4K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$50.4K |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$47K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$23K |
| 5 |
VF
Virtu Financial
New York
|
-$14K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BRWA
26
B. Riley Wealth Advisors
Boca Raton,
Florida
| – | -$4K | -1,061 | Closed |
|
27
Millennium Management
New York
| – | -$3K | -880 | Closed |
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$3 | +1 | +13% |
|
COCP Hedge Fund Activity: Q4 2022 in Review
21 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q4 2022, worth a combined $2.08M — down 47% from $3.95M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of COCP and 2 opened new positions — a net loss of 6 holders — while 3 trimmed existing stakes and 15 added.
The largest buyer was UBS Group, adding an estimated $11.7K. The largest seller was Renaissance Technologies, cutting an estimated $50.4K.
- 21 institutional investors held Cocrystal Pharma (COCP) as of Q4 2022, down from 27 in Q3 2022.
- Funds reported $2.08M of Cocrystal Pharma stock for Q4 2022, down 47% quarter-over-quarter.
- 2 funds opened new Cocrystal Pharma positions in Q4 2022 and 8 closed out, a net change of -6 holders.
- The largest Cocrystal Pharma buyer in Q4 2022 was UBS Group, an estimated $11.7K added.
- The largest Cocrystal Pharma seller in Q4 2022 was Renaissance Technologies, an estimated $50.4K sold.
Based on aggregated 13F filings for Q4 2022.